Syngene International has announced changes to its senior management team. Mr. Alex Del Priore is leaving the company with immediate effect. Dr. Rohtash Kumar has been appointed as Head of CDMO, Small and Large Molecule, effective December 1, 2025. These changes reflect the company’s ongoing efforts to optimize its organizational structure and leadership.
Leadership Transition
Syngene International has revealed adjustments within its senior management personnel. The announcement confirms the departure of a key executive and the appointment of a new leader to a critical role within the organization. The company anticipates that these structural modifications will enhance operational efficiency.
Executive Departure
Mr. Alex Del Priore, previously serving as Head of Large Molecules CDMO and a member of the Executive Committee, will be leaving Syngene International. This departure is by mutual consent and is effective immediately as of November 18, 2025.
New Appointment
Syngene has appointed Dr. Rohtash Kumar as the new Head of CDMO, Small and Large Molecule. He will also be a member of the Executive Committee. This appointment is effective from December 1, 2025. He brings a wealth of experience in pharmaceutical operations, R&D, and executive leadership.
Dr. Rohtash Kumar’s Background
Dr. Kumar has over two decades of experience. He most recently led Global Technology and Development at Veranova. His prior accomplishments include driving innovation in APIs, peptides, and biologics. He holds a Ph.D. in Organic Chemistry and an MBA.
Source: BSE
